These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 958545

  • 21. [Treatment of multiple sclerosis with antilymphocyte serum: results of a pilot study on 50 patients followed-up over a 4-year period (author's transl)].
    Lhermitte F, Marteau R, De Saxce H.
    Rev Neurol (Paris); 1979 Jun; 135(5):389-400. PubMed ID: 538387
    [Abstract] [Full Text] [Related]

  • 22. [Clinical aspects and pathogenesis of multiple sclerosis].
    Neu I, Rodiek S.
    Med Monatsschr; 1977 Jan; 31(1):11-7. PubMed ID: 836531
    [No Abstract] [Full Text] [Related]

  • 23. [Immunosuppressive treatment with azathioprine and antilymphocyte serum in myasthenia].
    Benelli L, Tacconi G, Casacchia M, Paolella P, Agnoli A.
    Riv Neurobiol; 1974 Jan; 20(14):87-105. PubMed ID: 4471382
    [No Abstract] [Full Text] [Related]

  • 24. [Non-specific immunosuppression and multiple sclerosis].
    Brochet B.
    Rev Neurol (Paris); 1998 Sep; 154(8-9):629-34. PubMed ID: 9809379
    [Abstract] [Full Text] [Related]

  • 25. Developments in immunosuppressive therapy.
    Daar AS.
    Transplant Proc; 1995 Oct; 27(5):2671-5. PubMed ID: 7482871
    [No Abstract] [Full Text] [Related]

  • 26. [The problem and value of therapy in multiple sclerosis].
    Hitzschke B, Meyer-Rienecker HJ, Buddenhagen F, Richter M.
    Psychiatr Neurol Med Psychol (Leipz); 1988 Oct; 40(10):598-608. PubMed ID: 3237866
    [Abstract] [Full Text] [Related]

  • 27. A comprehensive protocol for clinical trials in multiple sclerosis which favored azathioprine and corticosteroid as a type of treatment for the chronic progressive phase.
    Tourtellotte WW, Syndulko K, Baumhefner RW, Shapshak P, Osborne M.
    Neurology; 1988 Jul; 38(7 Suppl 2):83-6. PubMed ID: 3386848
    [No Abstract] [Full Text] [Related]

  • 28. [Treatment of progressive and severe forms of multiple sclerosis using a combination of antilymphocyte serum, azathioprine and prednisone. Clinical and biological results. Comparison with a control group treated with azathioprine and prednisone only. 4-year follow-up].
    Lhermitte F, Marteau R, de Saxcé H.
    Rev Neurol (Paris); 1987 Jul; 143(2):98-107. PubMed ID: 3299618
    [Abstract] [Full Text] [Related]

  • 29. Azathioprine in multiple sclerosis: the cons.
    Silberberg DH.
    Neurology; 1988 Jul; 38(7 Suppl 2):24-7. PubMed ID: 3290710
    [Abstract] [Full Text] [Related]

  • 30. Intensive immunosuppression in multiple sclerosis.
    Zaffaroni M, Ghezzi A, Comi G.
    Neurol Sci; 2006 Mar; 27 Suppl 1():S13-7. PubMed ID: 16708175
    [Abstract] [Full Text] [Related]

  • 31. Clinical usefulness of conventional fine needle aspiration cytology in kidney transplantation--influence of different immunosuppressive protocols.
    Almirall J, Sole M, Campistol JM, Muntane J, Bru C, Oppenheimer F, Andreu J, Revert L.
    Transplant Proc; 1992 Feb; 24(1):71-2. PubMed ID: 1539350
    [No Abstract] [Full Text] [Related]

  • 32. [Immunosuppressive therapy in kidney transplantation].
    Flatmark A.
    Tidsskr Nor Laegeforen; 1971 Aug 20; 91(23):1684-6. PubMed ID: 4106716
    [No Abstract] [Full Text] [Related]

  • 33. [Various immunological aspects of demyelinations. II. Attempts at the determination of immunological reactions in multiple sclerosis].
    Vymazal J, Krásenská-Dlabacová J.
    Cesk Neurol Neurochir; 1974 Jul 20; 37(4):240-6. PubMed ID: 4846373
    [No Abstract] [Full Text] [Related]

  • 34. Cyclosporine immunosuppression in non-heart-beating cadaver donors.
    Asano H, Uchida K, Tominaga Y, Haba T, Sato K, Numano M, Orihara A, Yokoyama I, Takagi H.
    Transplant Proc; 1992 Oct 20; 24(5):2042-3. PubMed ID: 1412965
    [No Abstract] [Full Text] [Related]

  • 35. Clinical experience with azathioprine: the pros.
    Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Nuwer MR.
    Neurology; 1988 Jul 20; 38(7 Suppl 2):20-3. PubMed ID: 3290709
    [Abstract] [Full Text] [Related]

  • 36. Comparative efficacy of prophylactic monoclonal (OKT3) and polyclonal antibodies (ATG) in immunologic high-risk renal transplant recipients.
    Fukuuchi F, Lefrançois N, Chapuis F, Gebuhrer L, Bosshard S, Dubernard JM, Touraine JL.
    Transplant Proc; 1996 Oct 20; 28(5):2808-9. PubMed ID: 8908070
    [No Abstract] [Full Text] [Related]

  • 37. [Multiple sclerosis].
    Igata A.
    Nihon Rinsho; 1970 Jul 20; 28(7):1886-91. PubMed ID: 4918043
    [No Abstract] [Full Text] [Related]

  • 38. Observations on prolonged immune suppression for human liver homografts.
    Fortner JG, Shiu MH, Balner H, Wilson CB, Sichuk G, Kawano N, Holmes JT, Beattie EJ.
    Transplant Proc; 1971 Mar 20; 3(1):383-6. PubMed ID: 4328810
    [No Abstract] [Full Text] [Related]

  • 39. Quadruple-drug therapy with antithymocyte globulin in the early postoperative period after liver transplantation.
    Schattenfroh N, Lange D, Bechstein WO, Blumhardt G, Lohmann R, Neuhaus P.
    Transplant Proc; 1993 Apr 20; 25(2):1968-9. PubMed ID: 8470245
    [No Abstract] [Full Text] [Related]

  • 40. Effect of duration of MALG therapy in a quadruple immunosuppressive protocol.
    Stratta RJ, D'Alessandro AM, Armbrust MJ, Pirsch JD, Sollinger HW, Kalayoglu M, Belzer FO.
    Transplant Proc; 1989 Feb 20; 21(1 Pt 2):1726-8. PubMed ID: 2652564
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.